Understanding how CAR T cell therapy works in solid tumors
Official title: Response and resistance to chimeric antigen receptor T cell therapy in human solid tumors using spatial multi-omics
Funded at University of Pennsylvania · NIH-10921797 · Data updated 2026-11-12
This study is looking at how well CAR T cell therapy works for people with solid tumors like pancreatic and prostate cancer, and it aims to find out what makes the treatment more or less effective by examining tissue samples from patients before and after therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 18, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $406,250 |
| NIH project number | 1DP5OD037346-01 |
| Project ID | NIH-10921797 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors, particularly those undergoing CAR T cell therapy for pancreatic or prostate cancer.
✕Less likely to help
Patients with hematologic malignancies or those not receiving CAR T cell therapy may not benefit from this research.
What this research studies
This research investigates the challenges faced by chimeric antigen receptor (CAR) T cells when treating solid tumors, such as pancreatic and prostate cancers. By using advanced spatial multi-omics technology, the study will analyze tissue samples from patients before and after CAR T cell therapy to identify factors that influence treatment response and resistance. The goal is to uncover specific interactions between CAR T cells, tumor cells, and immune cells that may affect the therapy's effectiveness. This research aims to improve CAR T cell therapy outcomes for patients with solid tumors.
Why it matters
Potential benefit: If successful, this research could lead to enhanced CAR T cell therapies that are more effective for patients with solid tumors.
How similar studies have gone: While CAR T cell therapy has shown success in blood cancers, this approach to solid tumors is relatively novel and has not been extensively tested.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Rech, Andrew John — University of Pennsylvania
- Study coordinator: Rech, Andrew John
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.